The RNA sequencing files for the transcriptome analysis of the gastric samples are available at SRA accession PRJNA503182. The RNA sequencing files for the transcriptome analysis of the NPC samples are available at SRA accession PRJNA501807.

Introduction {#sec001}
============

The Epstein-Barr Virus (EBV) is a major opportunistic pathogen that induces multiple malignancies including Burkitt (BL), Hodgkin (HL), diffuse large B cell lymphoma (DLBCL), primary effusion lymphomas (PEL) in coinfections with Kaposi sarcoma virus (KSHV), central nervous system lymphoma (CNS) and several carcinomas including gastric carcinoma (GC), and nasopharyngeal carcinoma (NPC) \[[@ppat.1008071.ref001]\]. EBV readily infects B-lymphocytes and induces continuous growth *in vitro*, however, infection of epithelial cells is much more difficult and cell lines and xenografts have been difficult to establish from NPC and GC \[[@ppat.1008071.ref001]\]. Several well studied NPC xenografts, C15 and C17 can be easily passaged in immunodeficient mice but cannot be cultivated *in vitro*, while the C666 cell line is a rare example of an NPC that can be cultivated *in vitro* and retains the EBV genome \[[@ppat.1008071.ref002]--[@ppat.1008071.ref004]\]. The AGS cell line was established from an EBV negative adenoma and is one of the few epithelial cell lines that can be infected with EBV \[[@ppat.1008071.ref005]\]. Different patterns of viral gene expression are characteristic of the distinct malignancies and are also observed in cell lines and xenografts \[[@ppat.1008071.ref001], [@ppat.1008071.ref006]\]. B-lymphocytes infected *in vitro* express six nuclear antigens (EBNA), two membrane proteins, the abundant pol 3 EBER transcripts, the BHRF1 miRNAs, and low levels of the non-coding BART RNAs \[[@ppat.1008071.ref007]\]. This pattern of expression is termed Type III latency. The C15 retains a pattern of EBV expression much like NPC and is considered Type II latency with expression of EBNA1, latent membrane protein 1 (LMP1), latent membrane protein 2 (LMP2), the non-coding Pol III EBER RNAs, and the non-coding BART RNAs (BamHI A rightward transcripts) \[[@ppat.1008071.ref006]\]. EBV infection of AGS cells mirrors EBV positive gastric cancer and consistently results in Type 1 latency with expression of EBNA1 and the BART RNAs \[[@ppat.1008071.ref008], [@ppat.1008071.ref009]\]. The BART RNAs are templates for 44 virally encoded miRNAs while the spliced polyadenylated BART RNAs remain nuclear and apparently function as long noncoding (lnc) RNAs with consistent effects on cell expression \[[@ppat.1008071.ref010], [@ppat.1008071.ref011]\]. Additionally, EBV infection of the AGS gastric cell line induces anchorage independent growth with major effects on cellular mRNA expression, despite the highly restricted Type I pattern of expression \[[@ppat.1008071.ref008]\]. Expression of a single form of the spliced BART RNAs had considerable effects on cellular expression indicative of lnc function \[[@ppat.1008071.ref011], [@ppat.1008071.ref012]\]. A recent study used orthotopic injection of the C666 cell line into the nasopharynx and also nasopharyngeal injection of AGS-EBV cells to evaluate tumor growth and metastasis \[[@ppat.1008071.ref013]\]. The study indicated that expression of the BART miRNAs increased *in vivo* and that they were major effectors of changes in growth *in vivo*. This study also reported that AGS-EBV cells did not form tumors subcutaneously but only when inoculated into the nasopharynx, although the original establishment of the AGS cells reported tumor growth subcutaneously \[[@ppat.1008071.ref014]\].

As the BART RNAs are the most abundant transcripts in both NPC and GC and are thought to primarily affect growth through effects on cellular expression, the parental AGS cell line, AGS-EBV cell line, and the C666 NPC cell line were inoculated both subcutaneously (sc) and intraperitoneally (ip) into immmunodeficient mice. Additionally, the NPC xenografts, C15 and C17, were inoculated (sc) and included for comparison. All cell lines with or without EBV formed tumors both sc and ip although the AGS tumors with EBV were visually quite distinct from the EBV negative AGS tumors. Proteomic and RNA Seq analysis indicated that cellular expression was very different in gastric cells compared to NPC and that cellular expression *in vitro* was very different from that observed during tumor formation *in vivo*. Interestingly there were surprising differences in the predicted upstream regulators in both the EBV positive and EBV negative lines and tumors.

Results {#sec002}
=======

EBV infection minimally affects growth rate *in vivo* {#sec003}
-----------------------------------------------------

The AGS, AGS-EBV, and C666 cell lines have previously been described \[[@ppat.1008071.ref003], [@ppat.1008071.ref005], [@ppat.1008071.ref014]\]. Additionally, as LMP1 is a potent EBV encoded oncogene, derivatives of the AGS-EBV cell lines were prepared that contained the pBABE expression vector with or without LMP1 coding sequences. Although LMP1 transcription could be detected at low levels, LMP1 protein was not detected and likely did not affect growth. Clone 1 is a clone of AGS-EBV that has been maintained separately but is not obviously distinct \[[@ppat.1008071.ref008]\]. However, these cell lines and tumors were also analyzed for increased statistical power. The mice were inoculated either subcutaneously (sc) or intraperitoneally (ip) ([Table 1](#ppat.1008071.t001){ref-type="table"}). All animals were sacrificed according to IACUC regulations based on physical appearance or distress. The tumors were identified and harvested ([Table 1](#ppat.1008071.t001){ref-type="table"}). Surprisingly, the tumors were grossly distinct at time of sacrifice with the AGS cells forming solid white tumors sc while the AGS-EBV tumors were soft with excessive amounts of blood. Histopathologic examination indicated that the AGS tumors had extensive necrosis ([Table 1](#ppat.1008071.t001){ref-type="table"}) and had evidence of differentiation in the IP injections. The AGS-EBV tumors also had some necrosis with considerable hemorrhage. The time to sacrifice did not obviously differ between the AGS parental cells and the collective AGS-EBV cells ([Table 1](#ppat.1008071.t001){ref-type="table"}, [Fig 1A](#ppat.1008071.g001){ref-type="fig"}) nor did the insertion of the pBABE expression vector to express LMP1 or vector control affect growth ([Table 1](#ppat.1008071.t001){ref-type="table"}). The apparent growth rate determined by tumor volume at time of harvest was also variable with clone 1 necessitating sacrifice slightly earlier ([Fig 1B](#ppat.1008071.g001){ref-type="fig"}). However, assessing tumor weight and combining all of the EBV positive tumors with or without exogenous vector in comparison with the AGS tumors revealed a slightly enhanced growth of the EBV positive tumors with borderline significance (P = 0.05) ([Fig 1C](#ppat.1008071.g001){ref-type="fig"}). To further investigate any growth stimulating effects induced by EBV, tumor lysates were analyzed by immune blotting for proliferating cell nuclear antigen (PCNA) as a marker for DNA synthesis \[[@ppat.1008071.ref015]\]. The detection was quantified, normalized to the cellular marker HSC70, and presented graphically relative to AGS tumors ([Fig 1D](#ppat.1008071.g001){ref-type="fig"}). The PCNA detection was also variable and did not reveal statistically significant differences. This is in agreement with the histologic determination of mitotic index which was similar in the AGS and AGS-EBV tumors but elevated in the NPC C666 tumors ([Table 1](#ppat.1008071.t001){ref-type="table"}). Haemotoxylin and eosin staining of the tumor tissues confirmed the presence of abundant red blood cells in the EBV^+^ gastric tumors as compared to the EBV^-^ gastric tumors ([Fig 1E](#ppat.1008071.g001){ref-type="fig"}).

![Survival, tumor growth, and proliferation rates of EBV^-^ AGS tumors and EBV^+^ AGS-EBV/Clone 1 tumors that develop in mice.\
(A) Kaplan-Meier survival plot of AGS injected mice and the AGS-EBV/Clone 1 injected mice as a function of days post injection subcutaneously (SC) or intraperitoneally (IP). (B) Average growth rate of the tumors post subcutaneous injection (SC) of the cell lines measured in tumor volume and days post injection. Graph of mean tumor volume at days post subcutaneous injection for each of the three cell lines, AGS; AGS-EBV and pB derivatives; and Clone1and pB derivatives. (C) Graph of mean tumor weight at harvest/days post injection at harvest of the AGS tumors (IP and SC) and the AGS-EBV and Clone1 and pB derivatives (IP and SC). (D) Western blot detection of PCNA in the IP and SC tumors that develop following injection of the AGS, AGS-EBV, and Clone1 cell lines and pB derivatives and quantification of the PCNA normalized to HSC70 as a loading control using the Image Lab software (Biorad). (E) Haemotoxylin and eosin staining of representative AGS, AGS-EBV, and Clone 1 tumors. Arrows denote presence of red blood cells.](ppat.1008071.g001){#ppat.1008071.g001}

10.1371/journal.ppat.1008071.t001

###### Tumor samples and histology.

![](ppat.1008071.t001){#ppat.1008071.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell line Injected   Route\         Number of tumors   Average time to harvest (days)   Average tumor weight (grams)   Average mitotic index[\*](#t001fn001){ref-type="table-fn"}   Histology Comments
                       of injection                                                                                                                                                   
  -------------------- -------------- ------------------ -------------------------------- ------------------------------ ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------
  AGS                  IP             4                  83                               0.72                           1.75 to 6                                                    Small dense nuclei, trying to form ducts, necrosis

  AGS-EBV              IP             1                  56                               0.93                           3 to 7                                                       Hemorrhage and necrosis

  Clone 1              IP             1                  48                               1.45                           4 to 11                                                      Masses of polygonal cell, large nuclei, more vascular, hemorrhage and necrosis

  C666.1               IP             4                  44                               2.52                           13 to 29                                                     Large cells and nucleoli, no necrosis or hemorrhage

  AGS                  SC             2                  145                              0.49                           3 to 7                                                       Masses of polygonal cells, hemorrhage and massive necrosis

  AGS-EBV              SC             2                  102                              1.45                           3 to 10                                                      Hemorrhage and necrosis

  AGS-EBVpB            SC             4                  133                              1.07                           2.3 to 7.3                                                   Very vascular, hemorrhage and necrosis, cuboidal to columnar cells sometimes forming variable sized glandular structures

  AGS-EBV pBLMP1       SC             3                  151                              1.70                           2.3 to 7.7                                                   Very vascular, hemorrhage and necrosis, cuboidal to columnar cells sometimes forming variable sized glandular structures

  Clone 1              SC             1                  86                               0.44                           [\*\*](#t001fn002){ref-type="table-fn"}                      necrosis

  Clone 1pB            SC             4                  82                               0.88                           5.25 to 13                                                   Solid sheets of tumor cells, necrosis, hemorrhage, vascular pools

  Clone 1 pBLMP1       SC             4                  82                               1.39                           2.3 to 11.3                                                  Massive necrosis, pools of blood, hemorrhage
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*number of mitosis per 40x magnification field

\*\*sample too necrotic

Distinct cellular protein expression in cell lines and tumors {#sec004}
-------------------------------------------------------------

We have previously shown that the BART RNAs including miRNAs and spliced RNAs are the most abundantly expressed RNAs in AGS-EBV cells \[[@ppat.1008071.ref009]\]. As miRNAs in part target protein abundance, differences in protein expression were identified using 2-D difference gel electrophoresis. Analysis using Decyder software identified 1812 spots that matched across all samples. Further analysis using Principal Component Analysis (PCA) revealed that PCA1 separated the tumors from the cell lines representing at least 60.5% of the variance between cell lines and tumors of both AGS and AGS-EBV and the C666 cell line compared with C666 tumors ([Fig 2A](#ppat.1008071.g002){ref-type="fig"}). This could reflect the presence of abundant mouse proteins contained within the mouse tumors grown *in vivo* in addition to growth *in vitro* compared to growth *in vivo*. Additionally, PCA2 completely distinguished AGS cell lines and tumors from the NPC C666 cell line and tumors ([Fig 2A](#ppat.1008071.g002){ref-type="fig"}). The identification of the specific proteins within the distinguishing spots requires considerable material and the resulting identification is frequently obscured by abundant contaminating proteins. These data were primarily obtained to reveal global similarities and differences. To determine more specific differences, the tumors were analyzed further using RNA sequence analysis.

![Principal component analysis based on 2D DIGE and RNA Seq analysis of the cell lines and tumors.\
(A) Principal component analysis of variation between proteins detected by 2D DIGE from the AGS, AGS-EBV, Clone1, pB derivatives, C666.1, and xenografts C15 and C17 cell lines and tumors. T represents tumors. (B) Principal component analysis based on variation between all expressed human transcripts from the AGS, AGS-EBV, Clone1, pB derivatives, C666.1, and xenografts C15 and C17 cell lines and tumors. (C) Principal component analysis based on variation between all expressed human transcripts from the AGS, AGS-EBV, Clone1, and pB derivatives gastric tumors. (D) Principal component analysis based on variation between all expressed mouse transcripts from the AGS, AGS-EBV, Clone1, and pB derivatives, C666.1, and xenografts C15 and C17 tumors. (E) Volcano plot of human gene expression of the pBabe derivative tumors vs the original cell line tumors. The few blue dots denote the significantly downregulated genes in the pBabe derivative tumors compared to the original cell line tumors and the red dots denote the significantly up regulated genes in the pBabe derivative tumors compared to the original cell line tumors.](ppat.1008071.g002){#ppat.1008071.g002}

### RNA sequence analysis distinguishes cell lines from tumors and NPC from AGS by principal component analysis {#sec005}

To more accurately identify effects on cellular expression, cell lines and all tumors including the NPC C15 and C17 tumors were analyzed by high throughput sequencing of polyadenylated selected RNA. The specific tumors, number of reads, aligned pairs, and mapped reads to human and mouse genomes are presented in [Table 2](#ppat.1008071.t002){ref-type="table"}. The number of reads mapping to the mouse genome (mm9) were quite variable and not obviously distinct between the sc or ip injections nor between the EBV positive and negative tumors ([Table 2](#ppat.1008071.t002){ref-type="table"}). Thus the distinct appearance of the EBV tumors with hemorrhage and increased blood did not represent invading mouse vessels. Interestingly, the percentage of reads mapping to the EBV genome decreased in the AGS-EBV tumors but not in the C666 NPC tumors ([Table 2](#ppat.1008071.t002){ref-type="table"}). There were very low levels of EBV expression in the C17 tumor as has been previously reported.

10.1371/journal.ppat.1008071.t002

###### TOPHAT summaries of reads to genomes.

![](ppat.1008071.t002){#ppat.1008071.t002g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample      Tumor and route   reads       Mapped reads to hg19   \%     Aligned pairs   Concordant pair alignment rate   Mapped reads to mm9   \%     Aligned pairs   Concordant pair alignment rate   Mapped reads to EBV (Akata)   \%      Aligned pairs   Concordant pair alignment rate
  ----------- ----------------- ----------- ---------------------- ------ --------------- -------------------------------- --------------------- ------ --------------- -------------------------------- ----------------------------- ------- --------------- --------------------------------
  AGS                           25120188    23234918               92.1   21366251        84.2                             260128                1.0    99700           0.4                                                                                    

  AGS         16(IP)            28216896    24374849               86.4   22551327        79.2                             2025183               7.9    1757384         6.2                                                                                    

  AGS         17(IP)            26507596    23108678               87.2   21308764        79.7                             1929337               7.3    16556132        6.2                                                                                    

  AGS         651(IP)           22396427    20218305               90.3   18932316        83.9                             1069744               4.8    893020          3.9                                                                                    

  AGS         652(IP)           23802126    14723414               61.9   13575398        56.5                             7676486               32.3   6800494         28.3                                                                                   

  AGS         105(SC)           22979420    19810978               86.2   18453532        79.6                             1867618               8,1    1616988         6.9                                                                                    

  AGS         106(SC)           22280936    16079045               72.2   14908180        66.3                             4969212               22.3   4555205         20.3                                                                                   

  AGS-EBV                       63677984    61050483               95.9   55912111        86.5                                                                                                           222169                        0.3     215243          0.3

  AE          19(IP)            115554194   105020890              90.9   95950977        81.9                             10910052              9.4    8382055         7.1                              124070                        0.1     119648          0.1

  AE          107(SC)           95288761    83594814               86.7   76687846        79.5                             11839257              12.3   9682229         10                               46259                         0.05    44639           0.05

  AE          185(SC)           78863727    55865269               70.8   51001626        63.9                             22673505              28.5   20124781        25.1                             104755                        0.1     100892          0.1

  AGS-EBVpB                     76574348    72369043               93.5   66446568        85.7                                                                                                           406864                        0.5     394791          0.5

  AEpB        415(SC)           71168887    58963301               81.9   54324259        75.5                             11627145              16.2   9895911         13.7                             87308                         0.1     83400           0.1

  AEpB        416(SC)           71226393    62539488               86.8   57492388        79.8                             8195312               11.4   6660533         9.2                              90672                         0.1     87286           0.1

  AEpB        417(SC)           70021038    53142325               75.0   48903732        69.1                             15968270              22.6   14065701        19.8                             144944                        0.2     139638          0.2

  AEpB        418(SC)           70833636    60015346               83.8   55335252        77.3                             9979711               14.0   8434505         11.7                             140395                        0.2     135882          0.2

  AGS-EBV\                      115047351   105960671              91.2   96953744        83.2                             2659357               2.3    115487          0.7                              471872                        0.4     456441          0.4
  pBLMP1                                                                                                                                                                                                                                                       

  AEL1        419(SC)           76758409    59412143               76.2   54335219        70.1                             16625202              21.4   14431891        18.6                             136432                        0.2     130460          0.2

  AEL1        421(SC)           78458488    66713274               84.1   61798325        78.0                             11130082              14.1   9379617         11.8                             150847                        0.2     144873          0.2

  AEL1        422(SC)           65292002    50066480               75.8   46191381        70.1                             14626619              22.2   12914443        19.6                             95393                         0.1     91901           0.1

  Clone1                        103048645   95658583               91.9   86967029        83.1                             2560564               2.5    756224          0.7                              1533526                       1.5     1486923         1.4

  CL1         18(1P)            78017990    59833811               75.4   54138969        68.5                             8557653               10.8   6900037         8.7                              71137                         0.1     67188           0.1

  CL1         186(SC)           65221956    55893900               84.7   51090533        77.4                             8935152               13.6   7365860         11.1                             87797                         0.1     84447           0.1

  CL1         187(SC)           110876987   79666811               71.0   72183118        64.2                             30720027              27.5   26950715        23.9                             161116                        0.1     155668          0.1

  Clone1pB                      82392572    74287997               89.2   67702984        80.9                             1930323               2.4    515442          0.6                              1381245                       1.7     1340724         1.6

  CL1pB       423(SC)           88917128    73074785               81.3   67189918        74.7                             15595795              17.4   13405332        14.9                             76208                         0.1     73506           0.1

  CL1pB       424(SC)           56750359    47420631               82.7   42716906        74.1                             8456178               14.9   7059000         12.2                             191995                        0.3     187045          0.3

  CL1pB       425(SC)           69238606    59374586               84.8   54491966        77.8                             8809215               12.6   7316106         10.4                             176411                        0.3     170509          0.2

  CL1pB       426(SC)           61840262    53720905               86.0   49830877        79.9                             7353930               11.8   6206115         9.9                              52634                         0.1     51146           0.1

  Clone1\                       64447535    58888159               90.3   53121229        81.1                                                                                                           346401                        0.5     334768          0.5
  pB LMP1                                                                                                                                                                                                                                                      

  C1L1        427(SC)           83151529    70175691               83.4   64199105        76.3                             12311478              14.7   10400537        12.3                             55651                         0.1     53723           0.1

  C1L1        428(SC)           69379810    60335980               86.2   55605976        79.2                             8262995               11.8   6818448         9.7                              120715                        0.2     116787          0.2

  C1L1        429(SC)           70559921    61249718               85.6   55952381        78.4                             9007046               12.6   7393909         10.3                             89335                         0.1     85940           0.1

  C1L1        430(SC)           71157444    58643359               81.3   53838297        74.9                             12037784              16.7   10306923        14.3                             55117                         0.1     53085           0.1

  C666.1                        74627397    72620949               96.3   65856734        86.7                             2006842               2.7    710300          0.9                              18744                         0.03    17851           0.03

  C666.1      22(IP)            69024264    62038997               88.9   56218304        80.0                             6915798               10.0   5445516         7.8                              27651                         0.04    26489           0.04

  C666.1      23(IP)            80733054    69690794               85.4   63089106        76.8                             10842027              13.4   8995581         11.0                             24602                         1.0     23525           1.0

  C666.1      103(IP)           56528824    51958245               90.9   46831925        81.3                             4395389               7.8    3244220         5.6                              16319                         0.03    15640           0.03

  C666.1      104(IP)           73297880    66607704               89.9   59772990        80.0                             6075264               8.3    4656778         6.2                              36845                         0.05    35264           0.05

  C15         2005              80772880    57955965               71.0   51735775        62.6                             22715151              27.9   19174495        22.6                             14842                         0.02    13039           0.02

  C15         2014              73537039    52267135               70.4   46737781        62.1                             20994674              28.3   17748882        22.9                             23042                         0.03    20688           0.03

  C17         1997              84853841    72291590               84.3   64454424        74.4                             12774604              15.0   10442092        12.0                             495                           0.001   454             0.001

  C17         2005              51557626    43374069               83.1   38171939        72.2                             8396243               16.2   6855026         12.9                             202                           0.001   185             0.001
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Aligned reads were mapped to specific human Refseq genes using the Partek Genomics Suite. Partek and Biojupies were used to identify differentially expressed genes, generate hierarchical clusters, and perform principal component analysis (PCA). PCA in comparison with the human genome indicated that PCA1 determined that approximately 20% of the distinction was between NPC and the AGS cell lines and the tumors. Each NPC consistently clustered distinctly ([Fig 2B](#ppat.1008071.g002){ref-type="fig"}). The C666 cell line clustered completely with the C666 tumors. This is interesting as C666 is a rare NPC that can grow as a cell line and these data confirm their similarity and identity \[[@ppat.1008071.ref003], [@ppat.1008071.ref004]\]. The AGS and AGS-EBV cell lines clustered together but were distinguishable from the tumors ([Fig 2B](#ppat.1008071.g002){ref-type="fig"}). PCA analysis did not distinguish the AGS tumors from the AGS-EBV tumors ([Fig 2B](#ppat.1008071.g002){ref-type="fig"}) nor whether the injection was sc or ip ([Fig 2B](#ppat.1008071.g002){ref-type="fig"}). However, comparison of just the AGS tumors with or without EBV delineated the two groups ([Fig 2C](#ppat.1008071.g002){ref-type="fig"}). Analysis of the differential expression of mouse genes did not reveal any clear differences between AGS or AGS-EBV tumors using principal component analysis ([Fig 2D](#ppat.1008071.g002){ref-type="fig"}). This suggests that the biologic difference in the amount of blood and hemorrhage reflects distinct growth properties of the AGS-EBV tumors from the AGS tumors that are likely due to differences in cellular expression within the AGS-EBV tumor cells and that the increased hemorrhage does not reflect infiltrating mouse tissue. To confirm that the addition of the pBabe vector did not significantly change the human or mouse gene expression in the AGS-EBV positive tumors as compared to the original cell line AGS-EBV tumors, volcano plots were generated comparing gene expression in the tumors, and very few genes were significantly changed ([Fig 2E](#ppat.1008071.g002){ref-type="fig"}).

### Canonical pathway analysis of tumors and cell lines {#sec006}

Genes altered two fold by growth *in vivo* or *in vitro* were sorted into categories based on the canonical pathways using IPA software. The categories that were highly enriched in the data sets, with the size of each bar corresponding to the log of the *P* value of enrichment, are presented graphically. The orange boxes indicate the relative number of genes in the data set within that pathway indicated by the ratio at the right end of the graphs in [Fig 3B and 3D](#ppat.1008071.g003){ref-type="fig"}. The orange line or threshold marks the p value of 0.05. Red bars indicate that the function is predicted to be activated, and blue bars indicate that the function is predicted to be inhibited based on the pattern of expression of these genes. Grey bars indicate that the function was predicted to be neither activated nor inhibited based on the data. Comparison of the AGS tumors to the AGS cell lines identified multiple pathways that had significant enrichment but could not be predicted to be activated or inhibited but were apparently affected indicating that multiple genes that contribute to these pathways differed in the tumors and cell lines ([Fig 3A](#ppat.1008071.g003){ref-type="fig"}). Pathways uniquely affected in the AGS tumor or the AGS-EBV tumors are indicated with astericks. Identification of only those pathways that had a significant predicted change evidenced by a z score change greater than 2 revealed that the majority of pathways were decreased in the tumors in comparison with the cell line ([Fig 3B](#ppat.1008071.g003){ref-type="fig"}). These included pathways likely involved in growing in adherent condition *in vitro* including NRF2 oxidative stress response, remodeling of adherans junctions, integrin signaling, signaling by rho family members, and interleukin signaling (ILK). Several pathways including actin cytoskeleton signaling, Rac signaling, Pac signaling, and Stat3 pathway were predicted to be uniquely downregulated in the AGS tumors compared to their cell line but not in the AGS-EBV tumors. Only Rho GDI signaling and PTEN signaling were activated and unique to the AGS tumors ([Fig 3B](#ppat.1008071.g003){ref-type="fig"}). Comparison of the AGS-EBV tumors to the AGS-EBV cell lines also identified multiple pathways in the data set without prediction of activation and also identified several of the same pathways identified in the AGS tumors, including ILK signaling, ERK/MAPK signaling, and epithelial adherans junction signaling. However, fewer pathways were predicted to be inhibited ([Fig 3C and 3D](#ppat.1008071.g003){ref-type="fig"}). The integrin, IL-8, and Rho GTPase signaling pathways were predicted to be inhibited with significant z scores in both the EBV positive and negative tumors as compared to their cell lines, but the ERK5 signaling pathway was specifically inhibited in the EBV positive tumors ([Fig 3D](#ppat.1008071.g003){ref-type="fig"}). Analysis of canonical pathways affected in AGS-EBV tumors in comparison with AGS tumors had few pathways significantly affected ([S1A Fig](#ppat.1008071.s001){ref-type="supplementary-material"}) with decreased activation of intrinsic prothrombin activation and phospholipases in the EBV positive AGS tumors ([S1B Fig](#ppat.1008071.s001){ref-type="supplementary-material"}). Interestingly several metabolic pathways including glutamine degradation and glucaronate degradation had multiple genes affected although neither activation nor inactivation was predicted ([S1A Fig](#ppat.1008071.s001){ref-type="supplementary-material"}).

![Canonical pathways associated with human genes with 2-fold expression changes by RNA Seq in gastric tumors when compared to the gastric cell lines.\
(A) Top canonical pathways associated with human genes with 2 fold expression change by RNA seq in the AGS tumors compared to AGS cell line. Astericks (\*) denote pathways unique to the comparison of AGS tumor to their cell line. (B) Significant canonical pathways (absolute z-score ≥2) associated with AGS tumors compared to AGS cell line. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set represented in the pathway. Astericks (\*) denote pathways unique to the comparison of AGS tumor to their cell line. (C). Top canonical pathways associated with human genes with 2-fold expression change by RNA seq in the AGS-EBV tumors when compared to the AGS-EBV and pB derivative cell lines. Astericks (\*) denote pathways unique to the comparison of AGS-EBV tumors to their cell lines. (D) Significant canonical pathways (absolute z-score ≥2) associated with AGS-EBV tumors compared to AGS-EBV and pB derivative cell lines. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set represented in the pathway. Astericks (\*) denote pathways unique to the comparison of AGS-EBV tumors to their cell lines.](ppat.1008071.g003){#ppat.1008071.g003}

In agreement with PCA, the analysis of the predicted canonical pathways from the gene expression in the C666 tumors as compared to the cell line did not identify any significant differences except in the predicted inhibition of calcium signaling in the tumors ([S2 Fig](#ppat.1008071.s002){ref-type="supplementary-material"}).

As expected, multiples pathways were significantly and uniquely changed when comparing the NPC tumors to the EBV negative and EBV positive gastric tumors. Three pathways involved in cholesterol biosynthesis were activated in the NPC tumors as compared to the gastric tumors while integrin signaling was predicted to be inhibited ([S3 Fig](#ppat.1008071.s003){ref-type="supplementary-material"}). 14-3-3 signaling and phospholipase signaling were apparently more important in the AGS tumors, while SAPK/JNK signaling was more important in the AGS-EBV tumors ([S3A and S3B Fig](#ppat.1008071.s003){ref-type="supplementary-material"}).

### Predicted upstream regulators are altered in tumors and indicate increased regulation by miRNAs {#sec007}

Potential upstream regulators of these changes in expression with significant p-values were also identified using IPA analysis. The vast majority, 23 in all, of the predicted activators of expression in the EBV negative AGS tumors were identified as miRNAs ([Table 3](#ppat.1008071.t003){ref-type="table"}). While the RNA Seq data of the tumors does not identify the mature miRNA, their expression in the cell lines was identified in previous studies \[[@ppat.1008071.ref009]\]. Several of these miRs were expressed in the AGS cell line. Several of the miRNAs predicted to be upstream regulators and activated in the tumors had a seed sequence similar to specific BART miRNAs ([Table 3](#ppat.1008071.t003){ref-type="table"}). Only 3 of the activated regulators which also had significant increase in expression were proteins including TCF3, COL18A1, and HNF1A. These findings suggest that regulation of growth *in vivo* by protein regulators is decreased and that significant regulation is mediated by noncoding RNAs.

10.1371/journal.ppat.1008071.t003

###### Upstream regulators predicted for AGS tumor vs AGS cell line.

![](ppat.1008071.t003){#ppat.1008071.t003g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upstream Regulator[\*](#t003fn001){ref-type="table-fn"}   Expr Fold Change[\*\*](#t003fn002){ref-type="table-fn"}   Molecule Type[\*\*\*](#t003fn003){ref-type="table-fn"}                            Predicted Activation State   Activation\   p-value of overlap   \# of target molecules in dataset with expression consistent with activation or inhibition
                                                                                                                                                                                                                                     z-score                            
  --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------- ------------- -------------------- --------------------------------------------------------------------------------------------
  MYC                                                       -2.69                                                     transcription regulator                                                           Inhibited                    -5.027        4.16E-16             95/167

  **E2F3**                                                  -1.58                                                     transcription regulator                                                           Inhibited                    -3.376        3.65E-13             24/44

  E2F2                                                      -2.07                                                     transcription regulator                                                           Inhibited                    -2.673        4.81E-13             12/27

  **CCND1**                                                 -3.58                                                     transcription regulator                                                           Inhibited                    -4.075        1.35E-11             30/58

  **ATF4**                                                  -1.75                                                     transcription regulator                                                           Inhibited                    -4.656        2.24E-10             32/39

  TCF7L2                                                    -1.61                                                     transcription regulator                                                           Inhibited                    -3.259        7.47E-09             40/59

  **KRAS**                                                  -1.99                                                     enzyme                                                                            Inhibited                    -3.33         9.36E-07             31/70

  **EDN1**                                                  -9.45                                                     cytokine                                                                          Inhibited                    -4.065        8.33E-06             27/36

  **CSF2**                                                  turned off in tumor                                       cytokine                                                                          Inhibited                    -5.457        1.13E-05             49/65

  **SREBF2**                                                -2.82                                                     transcription regulator                                                           Inhibited                    -2.482        2.53E-05             14/18

  **CCNE1**                                                 -2.29                                                     transcription regulator                                                           Inhibited                    -2.121        3.74E-05             7/9

  MKL1                                                      -1.82                                                     transcription regulator                                                           Inhibited                    -3.223        4.03E-05             15/26

  **FOXO1**                                                 -4.25                                                     transcription regulator                                                           Inhibited                    -2.804        5.97E-05             29/51

  **ETS1**                                                  -6.58                                                     transcription regulator                                                           Inhibited                    -3.061        9.77E-05             15/35

  **EGFR**                                                  -8.76                                                     kinase                                                                            Inhibited                    -3.798        0.000141             36/53

  **AIF1**                                                  -8.41                                                     other                                                                             Inhibited                    -2.236        0.00201              5/5

  CREB1                                                     -1.72                                                     transcription regulator                                                           Inhibited                    -2.962        0.00318              36/65

  **HIF1A**                                                 -3.72                                                     transcription regulator                                                           Inhibited                    -2.212        0.00501              25/48

  **MAP2K1**                                                -2.21                                                     kinase                                                                            Inhibited                    -2.553        0.00541              14/25

  MET                                                       -3.78                                                     kinase                                                                            Inhibited                    -3.208        0.0071               13/15

  EIF4E                                                     -1.82                                                     translation regulator                                                             Inhibited                    -3.299        0.0107               16/20

  **KLF5**                                                  -1.87                                                     transcription regulator                                                           Inhibited                    -2.016        0.0136               8/10

  DBI                                                       -1.72                                                     other                                                                             Inhibited                    -2            0.0143               4/4

  **MAP2K4**                                                -1.53                                                     kinase                                                                            Inhibited                    -2.595        0.0195               7/10

  **CCNK**                                                  -1.89                                                     kinase                                                                            Inhibited                    -2.376        0.0362               6/6

  **PRKCE**                                                 -3.15                                                     kinase                                                                            Inhibited                    -2.745        0.0376               10/11

  **IL15**                                                  turned off in tumor                                       cytokine                                                                          Inhibited                    -2.288        0.0394               16/41

  **let-7 (MIRLET7BHG)**                                    3.24                                                      microrna                                                                          Activated                    4.771         9.45E-10             33/37

  miR-16-5p (miRs w/seed AGCAGCA)                           exp in cell line                                          mature microrna BART-20-5p AGCAG**G**C                                            Activated                    4.654         1.12E-07             36/41

  miR-1-3p                                                  not exp in cell line                                      mature microrna                                                                   Activated                    3.413         1.96E-06             29/37

  miR-124-3p                                                                                                          mature microrna                                                                   Activated                    4.427         4.75E-05             35/41

  miR-34a-5p                                                2.57                                                      mature microrna                                                                   Activated                    2.485         1.59E-05             12/15

  miR-155-5p (miRs w/seed UAAUGCU)                          not exp in cell line                                      mature microrna BART14 **A**AATGCT                                                Activated                    3.899         1.7E-05              26/30

  miR-21-5p                                                 not exp in cell line                                      mature microrna                                                                   Activated                    2.957         1.97E-05             14/16

  miR-503-5p (miRs w/seed AGCAGCG)                          not exp in cell line                                      mature microrna BART1-3p AGCA**C**CG BART2-3p AG**G**AGCG BART20-5p AGCAG**GC**   Activated                    2.586         5.96E-05             7/7

  **TCF3**                                                  2.41                                                      transcription regulator                                                           Activated                    3.285         0.000205             22/35

  miR-30c-5p                                                exp in cell line                                          mature microrna                                                                   Activated                    3.177         0.000265             18/21

  **let-7a-5p**                                             3.24                                                      mature microrna                                                                   Activated                    3.577         0.000313             22/26

  miR-291a-3p                                                                                                         mature microrna                                                                   Activated                    4.217         0.000331             18/18

  mir-122                                                   not exp in cell line                                      microrna                                                                          Activated                    3.765         0.000331             17/18

  miR-145-5p                                                exp in cell line                                          mature microrna                                                                   Activated                    2.021         0.000738             10/13

  mir-21                                                    highly exp in cell line                                   microrna                                                                          Activated                    4.475         0.000781             32/37

  mir-15                                                    exp in cell line                                          microrna                                                                          Activated                    2.255         0.00125              9/12

  miR-199a-5p                                               not exp in cell line                                      mature microrna                                                                   Activated                    2.244         0.00184              11/14

  miR-133a-3p                                               not exp in cell line                                      mature microrna                                                                   Activated                    2.596         0.00296              10/11

  mir-34 (MIR34HG)                                          2.57                                                      microrna                                                                          Activated                    2.39          0.0036               9/10

  COL18A1                                                   11.59                                                     other                                                                             Activated                    3.333         0.0071               14/15

  **HNF1A**                                                 43.15                                                     transcription regulator                                                           Activated                    2.88          0.00765              22/52

  miR-30a-3p                                                exp in cell line                                          mature microrna                                                                   Activated                    2.447         0.0102               6/6

  miR-29b-3p (miRs w/seed AGCACCA)                          exp in cell line                                          mature microrna BART1-3p AGCACC**G**                                              Activated                    3.249         0.0135               11/11

  miR-26a-5p                                                highly exp in cell line                                   mature microrna                                                                   Activated                    2.388         0.0224               6/6

  miR-92a-3p                                                highly exp in cell line                                   mature microrna                                                                   Activated                    2.412         0.0265               6/6

  miR-203a-3p                                               exp in cell line                                          mature microrna                                                                   Activated                    2.236         0.033                5/5
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Bolded font denotes genes with fold change in expression with p value and FDR \<0.05, regular font denotes fold change in expression with p\<0.05

\*\*EBV miR expression from \[[@ppat.1008071.ref009]\]

\*\*\*Bolded font denotes base change in EBV miR

Similarly, in the AGS-EBV tumors, many protein regulators were predicted to be inhibited ([Table 4](#ppat.1008071.t004){ref-type="table"}). Four protein regulators that were activated included ALDH2, COL18A1, TRIM24, and HDAC1. The activation of HDAC1 uniquely in the EBV positive tumors also suggests the importance of epigenetic regulation during tumor formation. Activated regulators also included 4 miRNAs with two that differed from those detected in the AGS tumors, miR-8 and miR-27a-3p. It is possible that EBV BART miRNAs or lnc RNAs may substitute for some of the activated miRNAs in the AGS tumors.

10.1371/journal.ppat.1008071.t004

###### Upstream regulators predicted for AGS-EBV tumors vs cell lines.

![](ppat.1008071.t004){#ppat.1008071.t004g}

  Upstream Regulator[\*](#t004fn001){ref-type="table-fn"}   Expr Fold Change[\*\*](#t004fn002){ref-type="table-fn"}   Molecule Type                Predicted Activation State   Activation z-score   p-value of overlap   \# of target molecules in dataset with expression consistent with activation or inhibition
  --------------------------------------------------------- --------------------------------------------------------- ---------------------------- ---------------------------- -------------------- -------------------- --------------------------------------------------------------------------------------------
  **ATF4**                                                  -1.95                                                     transcription regulator      Inhibited                    -5.913               8.09E-32             47/63
  **EGFR**                                                  -5.84                                                     kinase                       Inhibited                    -3.09                2.09E-13             41/67
  **HIF1A**                                                 -1.78                                                     transcription regulator      Inhibited                    -2.581               1.65E-12             39/75
  **NUPR1**                                                 -3.76                                                     transcription regulator      Inhibited                    -4.638               3.16E-12             67/91
  **EDN1**                                                  -2.76                                                     cytokine                     Inhibited                    -3.873               5.5E-11              32/47
  **SRF**                                                   -1.53                                                     transcription regulator      Inhibited                    -3.017               2.41E-10             21/64
  **DDIT3**                                                 -3.32                                                     transcription regulator      Inhibited                    -2.374               4.0E-09              15/21
  **EP300**                                                 -1.33                                                     transcription regulator      Inhibited                    -2.052               6.99E-08             17/69
  **MAP2K1**                                                -1.45                                                     kinase                       Inhibited                    -2.976               1.1E-07              22/37
  **EZH2**                                                  -1.55                                                     transcription regulator      Inhibited                    -2.533               2.29E-07             23/52
  **EGR1**                                                  -18.54                                                    transcription regulator      Inhibited                    -2.071               2.36E-07             19/37
  **NOTCH1**                                                -2.75                                                     transcription regulator      Inhibited                    -2.71                4.58E-07             26/43
  **MAP2K1/2**                                              -1.4/-1.5                                                 group                        Inhibited                    -3.516               1.02E-06             17/19
  **MET**                                                   -2.87                                                     kinase                       Inhibited                    -2.429               2.24E-06             16/22
  **IPMK**                                                  -1.51                                                     kinase                       Inhibited                    -3.111               4.49E-06             10/10
  **FOXO1**                                                 -1.55                                                     transcription regulator      Inhibited                    -2.082               6.13E-06             29/54
  **TGFA**                                                  -1.79                                                     growth factor                Inhibited                    -3.249               9.43E-06             15/20
  **IRS1**                                                  -2.58                                                     enzyme                       Inhibited                    -2.088               1.02E-05             7/26
  **YAP1**                                                  -1.46                                                     transcription regulator      Inhibited                    -2.632               1.58E-05             9/19
  **CREB1**                                                 -1.57                                                     transcription regulator      Inhibited                    -3.564               1.65E-05             43/75
  **RPS6KA5**                                               -5.14                                                     kinase                       Inhibited                    -2.147               1.76E-05             7/8
  **KLF5**                                                  -1.79                                                     transcription regulator      Inhibited                    -2.094               2.72E-05             11/15
  **IGF1R**                                                 -1.50                                                     transmembrane receptor       Inhibited                    -3.25                4.37E-05             22/38
  **PPRC1**                                                 -1.44                                                     transcription regulator      Inhibited                    -3.046               5.9E-05              12/13
  **TEAD1**                                                 -1.61                                                     transcription regulator      Inhibited                    -2.157               6.93E-07             7/11
  **F2RL1**                                                 -2.42                                                     g-protein coupled receptor   Inhibited                    -2.011               0.000141             9/14
  **PRKCE**                                                 -4.49                                                     kinase                       Inhibited                    -3.669               0.00027              15/16
  **MAP2K4**                                                -1.15                                                     kinase                       Inhibited                    -3.127               0.000637             10/13
  **GAST**                                                  -23.17                                                    other                        Inhibited                    -2.509               0.000698             13/16
  **CREM**                                                  -1.46                                                     transcription regulator      Inhibited                    -2.091               0.000855             15/25
  **ELF4**                                                  -1.80                                                     transcription regulator      Inhibited                    -2.137               0.000999             7/9
  **NFATC3**                                                -1.38                                                     transcription regulator      Inhibited                    -2.374               0.00107              8/13
  **RHOB**                                                  -1.51                                                     enzyme                       Inhibited                    -2.2                 0.00308              5/5
  **Stat3-Stat3**                                           -1.31                                                     complex                      Inhibited                    -2.415               0.0128               6/6
  **CDKN1A**                                                -4.69                                                     kinase                       Inhibited                    -2.799               0.0285               15/27
  **CARM1**                                                 -1.36                                                     transcription regulator      Inhibited                    -2.383               0.0375               6/7
  **CHUK**                                                  -1.45                                                     kinase                       Inhibited                    -2.416               5.2E-07              23/40
  **ALDH2**                                                 1.76                                                      enzyme                       Activated                    3.45                 7.07E-08             12/12
  **COL18A1**                                               2.07                                                      other                        Activated                    3.703                2.17E-07             21/24
  **TRIM24**                                                2.12                                                      transcription regulator      Activated                    2.496                0.0329               11/14
  **HDAC1**                                                 1.50                                                      transcription regulator      Activated                    2.324                3.74E-09             2050
  miR-199a-5p (miRs w/seed CCAGUGU)                         exp in cell line                                          mature microrna              Activated                    2.712                5.42E-05             14/17
  miR-30c-5p (miRs w/seed GUAAACA)                          exp in cell line                                          mature microrna              Activated                    2.584                9.86E-05             17/22
  mir-8                                                                                                               microrna                     Activated                    2.555                0.000627             13/15
  miR-27a-3p (miRs w/seed UCACAGU)                          exp in cell line                                          mature microrna              Activated                    2.607                0.0375               7/7

\*Bolded font denotes genes with fold change in expression with p value and FDR \<0.05, regular font denotes fold change with p\<0.05

\*\*miR expression from \[[@ppat.1008071.ref009]\]

However, comparison of upstream regulators in EBV positive AGS tumors to EBV negative AGS tumors revealed effects on multiple pathways through both transcription factors and growth factors ([Table 5](#ppat.1008071.t005){ref-type="table"}). The predicted regulators were multiple genes previously shown to be affected by EBV including TNF, HIF1A, IL6, IRF7, and HNF1A which were predicted to be inhibited while CBX5, MAPK1,TP63, E2F3 were predicted to be activated ([Table 5](#ppat.1008071.t005){ref-type="table"}). These data are supported by the considerable numbers of genes detected in the data sets and the highly significant p-value of the overlap. It is intriguing that most of the predicted upstream regulators were inhibited in both EBV positive and negative tumors whereas miRNAs were primarily identified as activators of expression, particularly in the EBV negative AGS tumors ([S1 Table](#ppat.1008071.s005){ref-type="supplementary-material"}).

10.1371/journal.ppat.1008071.t005

###### Upstream regulators predicted for AGS-EBV tumors vs AGS tumors.

![](ppat.1008071.t005){#ppat.1008071.t005g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upstream Regulator[\*](#t005fn001){ref-type="table-fn"}   Expr\         Molecule Type       Predicted Activation State   Activation z-score   p-value of overlap   \# target molecules in dataset with expression consistent with activation or inhibition
                                                            Fold\                                                                                                    
                                                            Change                                                                                                   
  --------------------------------------------------------- ------------- ------------------- ---------------------------- -------------------- -------------------- -----------------------------------------------------------------------------------------
  TNF                                                                     cytokine            Inhibited                    -2.804               6.54E-13             59/100

  **NUPR1**                                                 -1.92         transcription reg   Inhibited                    -3.483               1.1E-06              35/53

  IFNG                                                                    cytokine            Inhibited                    -2.62                6.41E-06             49/72

  CLDN7                                                     -1.17         other               Inhibited                    -2.173               0.000115             10/12

  **HIF1A**                                                 1.1           transcription reg   Inhibited                    -2.000               0.000556             17/31

  **TP53**                                                  1.31          transcription reg   Inhibited                    -2.015               0.000994             36/71

  IL6                                                                     cytokine            Inhibited                    -2.912               0.00941              40/78

  **let-7 (MIRLET7BHG)**                                    -2.54         microRNA            Inhibited                    -3.367               0.00103              20/23

  **IL1 (A/B)**                                             -1.45/-1.27   group               Inhibited                    -2.07                0.0248               18/29

  IRF7                                                      1.2           transcription reg   Inhibited                    -2.09                0.0369               12/16

  **HNF1A**                                                 -1.93         transcription reg   Inhibited                    -3.96                0.0393               23/35

  **CBX5**                                                  2.35          transcription reg   Activated                    3.657                4.31E-10             23/27

  **MAPK1**                                                 1.54          kinase              Activated                    2.723                6.39E-08             22/32

  CCND1                                                     -1.15         transcription reg   Activated                    2.64                 0.000144             19/41

  TP63                                                      1.5           transcription reg   Activated                    2.883                0.00793              38/67

  E2f **(E2F3)**                                            1.3           group               Activated                    2.112                0.011                10/15

  **TBX2**                                                  1.4           transcription reg   Activated                    2.35                 0.0304               8/9

  **EIF4G1**                                                1.64          translation reg     Activated                    2.449                0.033                5/5
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Bolded font denotes genes with fold change in expression with p value and FDR \<0.05, regular font denotes fold change in expression with p\<0.05.

Identification of the Disease and Functions affected in the EBV positive SC tumors compared with the EBV negative SC tumors identified increased DNA replication, cell growth and proliferation, cancer, cellular development, and hematological system development and function. These functions are in keeping with the enhanced tumor growth. Additionally, the predicted activation of hematopoietic progenitor cells may likely reflect the highly bloody appearance of the EBV positive AGS tumors ([Table 6](#ppat.1008071.t006){ref-type="table"}).

10.1371/journal.ppat.1008071.t006

###### Disease and functions predicted for AGS-EBV SC tumors vs AGS SC tumors.

![](ppat.1008071.t006){#ppat.1008071.t006g}

  Categories                                                                                                           Diseases or Functions Annotation                      p-Value    Predicted Activation State   Activation z-score   \# Genes in dataset
  -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------- ---------------------------- -------------------- ---------------------
  Cancer,Gastrointestinal Disease,Organismal Injury and Abnormalities                                                  Large intestine neoplasm                              2.06E-11   Decreased                    -2.19                712
  Cellular Movement,Hematological System Development and Function,Immune Cell Trafficking                              Cell movement of mononuclear leukocytes               0.000108   Decreased                    -2.008               53
  Organismal Survival                                                                                                  Organismal death                                      0.000202   Decreased                    -2.348               216
  DNA Replication, Recombination, and Repair                                                                           DNA replication                                       2.06E-06   Increased                    2.077                35
  Cell Death and Survival                                                                                              Cell survival                                         9.69E-06   Increased                    2.259                147
  Cell Morphology,Cellular Function and Maintenance                                                                    Homologous recombination repair of tumor cell lines   1.46E-05   Increased                    2.592                8
  Cellular Growth and Proliferation                                                                                    Colony formation of tumor cell lines                  6.25E-05   Increased                    2.109                39
  DNA Replication, Recombination, and Repair                                                                           Metabolism of DNA                                     9.18E-05   Increased                    2.011                44
  Cellular Development,Cellular Growth and Proliferation,Hematological System Development and Function,Hematopoiesis   Proliferation of hematopoietic progenitor cells       0.000457   Increased                    2.149                30
  Cancer                                                                                                               Cell transformation                                   0.000851   Increased                    2.442                45
  Cellular Development                                                                                                 Epithelial-mesenchymal transition                     0.00113    Increased                    2.197                27
  Hematological System Development and Function,Hematopoiesis,Tissue Morphology                                        Quantity of hematopoietic progenitor cells            0.00366    Increased                    2.419                44

### Hierarchical clustering of RNA sequence analysis {#sec008}

The RNA sequence data analyzed using hierarchical clustering based on differential expression of human genes clearly delineated the NPC from the gastric samples, the cell lines from the tumors, as well as the EBV negative gastric tumors from the EBV positive tumors ([Fig 4A](#ppat.1008071.g004){ref-type="fig"}). Interestingly, the AGS cell line was completely within the cell line cluster containing the EBV positive cell lines as had also been indicated by the PCA analysis. Additionally, the C666 cell line clustered with the NPC tumors and was completely separated from the AGS cell lines. Several distinct expression patterns were visible on the hierarchical heat map ([Fig 4A](#ppat.1008071.g004){ref-type="fig"}). Of the NPC samples, the C17 tumor was completely separated and had clear differences in expression. IPA analysis of one area (1) in which 176 genes were markedly increased in the gastric samples compared to the NPC samples, largely greater than four-fold, revealed that this region contained genes associated with cell proliferation, migration, invasion, and epithelial differentiation ([Fig 4A-1](#ppat.1008071.g004){ref-type="fig"}). When the fold expression of these genes in this area as compared to NPC were analyzed by IPA, activation of canonical pathways involved in lipid metabolism (glutathione detox and redox), differentiation (aldersterone signaling, angiogenesis, adipocyte signaling and ERK/MAPK signaling), platelet activation (GP6 signaling), and cardiovascular signaling (Enos signaling) were predicted ([Fig 4B](#ppat.1008071.g004){ref-type="fig"}). These pathways would lead to increased proliferation, transformation, migration, and invasion.

![Hierarchical clustering heat map of gene expression of all samples and analysis of genes in distinct areas.\
(A) Hierarchical clustering heat map of gene expression vs hg19 and the associated genes. Red denotes upregulation and blue denotes downregulation. The samples are identified by pathology (gastric and NPC), Tissue (gastric tumor, cell line, NPC tumor), Type (sc tumor, ip tumor, cell line), virus (EBV negative and EBV positive), and sample grouping (EBV negative vs EBV positive). Genes from the five distinct areas are listed. (B) IPA analysis for canonical pathways, upstream regulators, and disease and functions of the genes from Section 1. Genes that are upregulated in the gastric samples relative to the NPC.](ppat.1008071.g004){#ppat.1008071.g004}

An area was also identified that included 41 genes that were upregulated specifically in the AGS-EBV gastric tumors relative to all the other samples. These genes included 8 which are involved in vasculogenesis; EPHB2, GJA5, LRP8, NODAL, PROX1, STRA6, TBX4, and TMEM204 ([Fig 4A-\*](#ppat.1008071.g004){ref-type="fig"}).

The heat map also revealed an area with 90 genes which were down regulated in the EBV positive gastric and NPC tumors when compared to the EBV negative gastric tumors, and contained genes including CTSE (cathepsin E), CXCL17, ITB7 (integrin β7), PIGR, TNFS12, MUC5B (mucin), and TRPV2 that are involved in inflammatory response and movement of antigen presenting cells ([Fig 4A-2](#ppat.1008071.g004){ref-type="fig"}). IPA analysis of the expression change of these 90 genes linked them to canonical pathways involved in lipid metabolism (methylgloxal degradation, phospholipase C signaling and phospholipases) as well as autophagy pathways (phagasome maturation and autophagy), hematological system development (Jak1 and JAK3 in cytokine signaling) and immune response (leukotriene biosynthesis). These pathways suggest that in the AGS-EBV tumors cell migration and inflammatory responses are decreased, and the quantity of hematopoietic progenitor cells are increased ([Fig 5A](#ppat.1008071.g005){ref-type="fig"}). As described earlier the AGS-EBV tumors were noticeably bloodier than the AGS tumors upon gross examination ([Table 1](#ppat.1008071.t001){ref-type="table"}, [Fig 1E](#ppat.1008071.g001){ref-type="fig"}).

![Analysis of canonical pathways, upstream regulators, and disease and functions within the annotated sections of the hierarchical clustering heat map.\
IPA analysis of the genes from 3 of the distinct areas on the hierarchical clustering heat map. (A) Section 2. Genes that are downregulated in the EBV positive tumors relative to the EBV negative tumors. (B) Section 3. Genes that are downregulated in the gastric tumors relative to the gastric cell lines. (C) Section 4. Genes that are downregulated in the gastric samples relative to the NPC samples.](ppat.1008071.g005){#ppat.1008071.g005}

A fourth area ([Fig 4A-3](#ppat.1008071.g004){ref-type="fig"}) which had much higher expression in the cell lines contained 54 genes linked to amino acid metabolism (CTH, GCLM, and NOS2), migration (CYP1A1, FOSL1, GAST (gastrin), ITPKA, KLF6, NNMT,PSG1, SKAP1, and SLC3A2), and apoptosis and necrosis (CD55, CTH, FOSL1, GCLM, KLF6, NPPB, NR1D1, OSGIN1, PLK3, PRPH, PSG2, RASD1, and TXNRD1) ([Fig 4A-3](#ppat.1008071.g004){ref-type="fig"}). The canonical pathways associated with these 54 genes involved metabolic pathways (L-cysteine, glutathione, thioredoxin, γ-glutamyl cycle, and citrulline-nitric oxide cycle) and integrin related signaling pathways (ILK, epithelial adherens junction, and tight junction signaling) and suggested within the tumors there is decreased cell survival, gene expression, and organization of the cytoskeleton as compared to the cell lines ([Fig 5B](#ppat.1008071.g005){ref-type="fig"}).

A fifth area on the hierarchical heatmap contained 139 genes which were highly expressed in the NPC samples and decreased in the gastric samples. This region was composed of genes involved in CD40 signaling (MAP3K14 (NIK), ICAM1, PIK3CD, NFKB2 (p52), and JAK3), regulation of epithelial-mesenchymal transition (FZD8, TCF4, PIK3CD, NFKB2, and JAK3), and NFκB and PI3K signaling (MAP3K14, TLR5, PIK3CD, JAK3, and NFKB2), pathways shown to be activated in NPC ([Fig 4A-4](#ppat.1008071.g004){ref-type="fig"}). The genes CHRNA7, CORO1A, FAS, ICAM1, IL15RA, JAK3, LAPTM5, MMP19, PGLYRP2, PIK3CD, and VSIR linked to activation of T lymphocytes were also more highly expressed in the NPCs, as well as the genes ACVRL1, AFAP1L2, CHRNA7, ETNK2, FAS, FZD8, IL34, INSRR, JAK3, MAP3K14, MAP3K6, MYO3A, NUAK1, OBSCN, PAX6, and PIK3CD involved in protein phosphorylation pathways.

IPA predicted the canonical pathways CD40 signaling, NFκB signaling, and B cell receptor signaling to be inhibited in the gastric samples relative to the NPC ([Fig 5C](#ppat.1008071.g005){ref-type="fig"}). Immune cell trafficking and inflammatory response as well as gene expression were also predicted to be decreased in the gastric samples as compared to the NPC samples ([Fig 5C](#ppat.1008071.g005){ref-type="fig"}).

The upstream regulators of the genes from these areas were also noticeably different. The genes that were significantly downregulated in the NPC samples ([Fig 4A-1](#ppat.1008071.g004){ref-type="fig"}) as compared to the gastric samples that are involved in migration, invasion, and epithelial differentiation had predicted upstream regulators CBX5, CYP1B1, ETS2, TGFB1, BMP4, SYVN1, IFNG, and SMARCA4. Some of the regulators had major increases in expression in the gastric samples including ETS2, which was increased 22 fold in expression, BMP4, which was increased 71 fold, and IFNG ([Fig 4B](#ppat.1008071.g004){ref-type="fig"}).

IRF7, SIM1, IFNG, and HNF1A were predicted to be upstream regulators of the higher expressed genes in the EBV negative gastric tumors involved in cellular movement, inflammatory response, and immune cell trafficking ([Fig 5A](#ppat.1008071.g005){ref-type="fig"}). The genes that were significantly upregulated in the gastric cell lines as compared to the other samples and involved in amino acid metabolism, migration, apoptosis, adhesion, and necrosis had predicted upstream regulators CLDN7, HRAS, RNA pol 2 and PKcs ([Fig 4A-3](#ppat.1008071.g004){ref-type="fig"}). When analyzed with the expression changes, the upstream regulators associated with these genes and that were predicted to be inhibited in the gastric tumors included the transcription regulators MYC and NFκB, the Pkc kinases and MAPK8 (JNK) as well as CLDN7 ([Fig 5B](#ppat.1008071.g005){ref-type="fig"}).

ID2, ID3, TRAF3, TRAF5, REL, TNF and CD40, genes or pathways previously shown to be affected in NPC were the predicted upstream regulators for the pathways identified by the genes significantly upregulated in NPC on the heat map ([Fig 4A-4](#ppat.1008071.g004){ref-type="fig"}) and involved in CD40 signaling, EMT, NFKB signaling, and PI3K signaling. When the 139 genes were analyzed with the fold expression changes, upstream regulators TNF and REL were predicted to be inhibited in the gastric samples as compared to the NPC ([Fig 5C](#ppat.1008071.g005){ref-type="fig"}).

### Genes consistently changed with EBV infection {#sec009}

There were 240 genes that were consistently changed in the same direction in all the EBV positive samples as compared to the EBV negative samples. These included 166 genes which were upregulated and 74 which were down regulated ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}). The upregulated genes were predicted to lead to increased DNA repair and included the helicases DNA2, SMARCB1 and SMARCC; DNA repair genes MSH6, MCM6, and XRCC5; increased RNA transactivation and included transcription regulators GTF2H3, CCNT1, RARA, KHDRBS1, VOPP1 and NFE2L1; increased viral infection, and decreased survival ([S3A Table](#ppat.1008071.s007){ref-type="supplementary-material"}). Several proto-oncogenes were upregulated in the EBV positive samples, including MYBL1 and RAF1 ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}). Several kinases were also upregulated including NCK1, PRKACA, and TK1 ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}). The consistently downregulated genes were predicted to lead to decreased movement, survival, proliferation, and immune response and increased apoptosis ([S3B Table](#ppat.1008071.s007){ref-type="supplementary-material"}). The down regulated genes included two serine protease inhibitors SLPI and SERPINA3, cell adhesion genes CEACAM5 and CEACAM6, transcription regulators ELF3 and GATA6 ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}).

### Comparison of the top 100 downregulated and upregulated genes in the tumors and cell lines {#sec010}

To provide a more detailed look at the specific genes composing each data set, the top 100 down regulated and upregulated genes in each comparison are listed ([S4 Table](#ppat.1008071.s008){ref-type="supplementary-material"}). These data were then utilized to prepare Venn diagrams revealing the extent of overlap between each group ([Fig 6](#ppat.1008071.g006){ref-type="fig"}). The comparisons reveal that of the 100 genes downregulated in the AGS tumors compared with the AGS cell line, 33 are in common with the 100 genes downregulated in the AGS-EBV tumors compared with the AGS-EBV cell line ([Fig 6A](#ppat.1008071.g006){ref-type="fig"}). Analysis of the upregulated genes revealed that 13 were in common between the AGS-EBV tumors and AGS tumors ([Fig 6B](#ppat.1008071.g006){ref-type="fig"}). Of the 100 genes decreased in the AGS-EBV tumors compared with the AGS tumors, only 2 are in common with the 100 genes decreased in the AGS-EBV cell lines compared to the AGS cell line ([Fig 6A](#ppat.1008071.g006){ref-type="fig"}) while in the 100 upregulated genes 4 are in common between those affected in the AGS-EBV tumor and the AGS-EBV cell line ([Fig 6B](#ppat.1008071.g006){ref-type="fig"}). When the top 100 up regulated genes in the AGS-EBV cell lines as compared to the AGS cell line were analyzed, many are involved in viability and organization of the cytoplasm ([S5A Table](#ppat.1008071.s009){ref-type="supplementary-material"}). Morbidity and Mortality is predicted to be strongly decreased. It is likely that many of these functions are linked to the upregulation of BCL6 and TCF3 in the AGS-EBV cell line. The upregulated genes in the AGS-EBV tumors are predicted to increase migration and movement as well as amino acid phosphorylation ([S5B Table](#ppat.1008071.s009){ref-type="supplementary-material"}). These classifications may reflect the upregulation of FYN and LCK which are molecules identified in every category.

![Comparison of the top 100 down regulated and upregulated genes in the data sets.\
A. Venn diagrams showing comparisons of the top 100 down regulated genes in each data set presented in [S4 Table](#ppat.1008071.s008){ref-type="supplementary-material"}. B. Venn diagrams showing the comparison of the top 100 up regulated genes in each data set presented in [S4 Table](#ppat.1008071.s008){ref-type="supplementary-material"}.](ppat.1008071.g006){#ppat.1008071.g006}

### EBV transcription with identified splice junctions {#sec011}

To determine the EBV specific transcription, reads that did not map to the human and mouse genomes, were aligned to the Akata EBV sequence using Tophat. The transcripts were assembled using Cufflinks and further assembled and quantified using Cufflinks and Stringtie ([Fig 7](#ppat.1008071.g007){ref-type="fig"}). Comparison of the AGS-EBV cell line and tumors did not reveal any obvious differences with transcription of the same sequences. The most abundantly transcribed region was from the BART noncoding locus ([Fig 7A](#ppat.1008071.g007){ref-type="fig"} and [Table 7](#ppat.1008071.t007){ref-type="table"}). Identification of the specific transcripts revealed that the AGS-EBV cell line was relatively permissive with expression of replicative genes from both strands. Additionally, multiple transcripts were identified that spliced into the BART locus. Comparison with the NPC samples, C15 and C666, revealed that the NPC samples remained tightly latent with considerably lower levels of transcription ([Fig 7B](#ppat.1008071.g007){ref-type="fig"}). The C15 tumor had a scale of 605 EBV reads while the AGS-EBV sample had a scale of more than 2000 reads. In contrast to the AGS-EBV cell line, the tumors had more restricted expression with decreases in number of detected reads ([Table 2](#ppat.1008071.t002){ref-type="table"} and [Fig 7A](#ppat.1008071.g007){ref-type="fig"}). The tumors had consistent expression of the BART RNAs, EBNA1 and LMP2. Additionally, the cell lines had greater evidence of transcription of replicative genes from the opposite strand while the tumors retained some replicative expression. Interestingly most of the tumors had consistent expression of BHRF1 and BHLF1 and some transcription of R/Z. The C15 and C666 tumors were similar with consistent expression of the BART RNAs, EBNA1, and LMP2 while reads from BHRF and BHLF1 were detected in C666 tumors and LMP1 in C15 ([Fig 7B](#ppat.1008071.g007){ref-type="fig"} and [Table 7](#ppat.1008071.t007){ref-type="table"}). In almost all of the gastric tumors, there was an increase in reads from the BARTs when compared to the cell lines, and fewer reads from BHLF1, EBNA1 and R/Z, and LMP2 ([Fig 7A](#ppat.1008071.g007){ref-type="fig"} and [S4 Fig](#ppat.1008071.s004){ref-type="supplementary-material"}). Interestingly abundant transcription was detected immediately upstream of the BART region at approximately 130 kb on the EBV genome only in the AGS-EBV cell lines and tumors ([Fig 7A](#ppat.1008071.g007){ref-type="fig"} and [S4 Fig](#ppat.1008071.s004){ref-type="supplementary-material"}). In the tumors from 13--100% of the previously described BART transcripts contained exons splicing from this upstream area. This region of transcription contains multiple putative ORFs. The AGS-EBV and Clone 1 cell lines and tumors also had a considerable peak of reads between 140 and 143 kb on the Akata genome within the LF3 region ([Fig 7A](#ppat.1008071.g007){ref-type="fig"} and [S4 Fig](#ppat.1008071.s004){ref-type="supplementary-material"}). Analysis of splice junctions indicated that in cell lines with abundant replicative expression, transcripts could be detected that spliced from EBNA1 into the BART complex ([Table 7](#ppat.1008071.t007){ref-type="table"}). Additional aberrant splice junctions were detected including BXLF/BDLF to BHLF, BNLF/LF3 to BHLF1, and oriLyt/LF3 to BHLF. These splices may indicate decreased regulation of splicing during replication or potential detection of circular RNAs that have been detected by RNA Seq \[[@ppat.1008071.ref016]\]. However, the abundant and consistent expression of the BART transcripts suggests that they are likely major effectors of EBV on cellular expression in both the EBV infected AGS cell line and AGS and NPC tumors.

![Visualization of the EBV reads and splice junctions.\
(A) Mapped reads and splice junctions of AGS-EBV cell lines and representative tumors mapped to the Akata genome. The scale in parentheses represents the number of reads with the height of the blue peaks also representing the abundance of reads. The EBV splice junctions are shown below in red with their corresponding EBV gene denoted on the bottom axis with the thickness of the red lines indicating the frequency of detection of specific splices. (B) Mapped reads and splice junctions of NPC cell line and tumors mapped to the Akata genome. The scale in parentheses represents the number of reads with the height of the blue peaks also representing the abundance of reads. The EBV splice junctions are shown below in red with their corresponding EBV gene denoted on the bottom axis with the thickness of the red lines indicating the frequency of detection of specific splices.](ppat.1008071.g007){#ppat.1008071.g007}
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###### Average percent of EBV spliced transcripts from Cufflinks and Stringtie[\*](#t007fn001){ref-type="table-fn"}.

![](ppat.1008071.t007){#ppat.1008071.t007g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample        LMP2   EBNALP/\   EBNA3   BHLF1                                        BHRF1                                        EBNA1   BSLF/\   Z/R-Z   BBLF   BGRF/\   BXLF\                                       BARTs\    \% BARTs with\   LF3                                          LMP1
                       EBNA2                                                                                                                BMLF                    BDRF     gH/TK                                       total     upstream exons                                                
  ------------- ------ ---------- ------- -------------------------------------------- -------------------------------------------- ------- -------- ------- ------ -------- ------------------------------------------- --------- ---------------- -------------------------------------------- ------
  **AGS-EBV**   4.9                       3.7                                          10.9                                         13.4             8.0     6.7                                                         44.7      100.0                                                         7.8

  AE 19         6.4                       1.1                                          29.3                                         5.4     3.3      4.8     4.3    1.1                                                  39.8      50.0                                                          4.6

  AE 107        17.5                      1.7                                          12.1                                                 2.2      2.2     0.7                                                         61.4      40.8                                                          2.3

  AE 185        11.1                      0.7                                          16.2                                         2.3     7.4      2.0     0.9                                                         59.5      37.9                                                          

  **AEpB**      23.3              13.3    4.6[^1^](#t007fn002){ref-type="table-fn"}                                                 4.9              13.2                    4.6[^1^](#t007fn002){ref-type="table-fn"}   25.5      72.6                                                          14.9

  AEpB 415      10.0                      2.1                                          5.0                                          1.1     0.9      0.6                     0.6                                         79.7      94.0                                                          

  AEpB 416      13.4                      12.6                                         18.5                                         0.5     1.1      2.1     1.1    0.4                                                  50.3      47.8                                                          

  AEpB 417      16.6                      3.3                                          28.4                                         0.9     3.7      1.4     0.9    0.5      0.6                                         43.7      100.0                                                         

  AEpB 418      7.9                       1.7                                          17.4                                         1.6     2.4      1.6     1.2    0.9      0.5                                         64.7      50.0                                                          

  **AEL1**      6.3                       0.3                                          18.5                                         5.7     15.1     5.1     9.2    4.7                                                  23.3      74.0                                                          11.8

  AEL1 419      5.3                       4.9                                          19.9                                         2.8     4.3      1.9     1.3    0.3                                                  59.2      44.3                                                          

  AEL1 421      8.4                       1.1^2^                                       12.8                                         1.0     0.5      0.9     0.3    0.3      0.3                                         74.3      63.3             0.5[^2^](#t007fn003){ref-type="table-fn"}    

  AEL1 422      16.8                      4.8                                                                                       9.8     2.4      4.8     0.7             0.8                                         60.0      23.6                                                          

  **Clone1**    48.6   5.8                                                             27.5[^3^](#t007fn004){ref-type="table-fn"}                    3.8     0.5             1.2                                         11.3^3^   100.0                                                         1.5

  CL1 18        6.8                       7.0                                          3.1                                          0.8     2.1      1.1                     1.4                                         77.8      60.4                                                          

  CL1 186       9.1                       8.1                                          33.9                                         5.0     15.9     2.2     6.3                                                         19.5      92.1                                                          

  CL1 187       10.0                      0.2                                                                                       26.5             12.8    16.9   6.3                                                  18.8      89.9             0.5                                          8.1

  **CL1pB**     14.9   10.0       0.8     16.3[^4^](#t007fn005){ref-type="table-fn"}   12.5[^5^](#t007fn006){ref-type="table-fn"}   7.4              9.7                                                                 18.9      66.3^5^          12.1[^4^](#t007fn005){ref-type="table-fn"}   9.3

  CL1pB 423     10.2                      2.3                                          23.7                                         3.7     7.0      3.7     4.8    0.8                                                  43.7      54.8                                                          

  CL1pB 424     3.4               0.1     10.3[^6^](#t007fn007){ref-type="table-fn"}   45.9                                         1.2     6.3      2.3     5.0    0.9                                                  24.6      13.7             10.3[^6^](#t007fn007){ref-type="table-fn"}   

  CL1pB 425     15.4                      1.7                                          24.4                                         8.5              5.5     12.2            0.2                                         32.1      50.0                                                          

  CL1pB 426     24.9                      4.0                                          19.5                                         1.9     14.2     4.6     1.6    9.5                                                  19.6      50.0                                                          

  **CL1L1**     8.9                       1.2                                          0.3                                          19.3    3.1      9.8     4.4    11.8                                                 35.6      78.9                                                          5.5

  C1L1 427      11.5                      1.6                                          42.3                                         4.9     7.0      3.1     6.3    5.0                                                  12.6      47.0                                                          5.8

  C1L1 428      9.9                       2.7                                          32.0                                         3.9     6.7      4.6     13.0                                                        27.1      34.9                                                          

  C1L1 429      5.5                       3.7                                          30.8                                         12.3             3.8     3.7                                                         40.2      36.4                                                          

  C1L1 430      5.7                       0.3                                          36.4                                         6.3                      2.1    5.1                                                  44.1      92.0                                                          

  **C666.1**    3.3                       3.4                                          0.4                                          2.2     0.7                                                                          90.0                                                                    

  C666 22       4.9                       2.1                                          5.0                                          4.0     9.0      1.6     0.2                                                         73.1                                                                    

  C666 23       2.6                       2.9                                          1.4                                          2.6     4.4      0.5     0.5             0.1                                         85.0                                                                    

  C666 103      3.1                       2.0                                          5.2                                          2.3     7.5      1.6                                                                 78.2                                                                    

  C666 104      6.1                       2.2                                          8.2                                          1.8     12.9     2.8     1.1    1.3      1.0                                         62.6                                                                    

  C15 2005      17.0                                                                                                                2.6                                                                                  33.1                                                                    47.4

  C15 2014      12.4                                                                                                                3.8                                                                                  74.8                                                                    9.0

  C17 1997                                                                                                                                                                                                               100.0                                                                   

  C17 2005                                                                                                                                                                                                               100.0                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Based on FPKMs (Fragments Per Kilobase of transcript per Million mapped reads) Total FPKM of distinct transcript/total FPKMs of all transcripts (average of Cufflink and Stringtie)

^1^ BHLF splices from BXLF/BDLF in AEpB (130435--119179 v 40093--37879)

^2^ 50% BHLF1 splices from BNLF/LF3 in AEL1 421 (169339--143022 v 40093--37252)

^3^ 60% of BART transcripts splice upstream from BWRF/BHRF in Clone1

^4^ 75% of BHLF transcripts splice from orilyt/LF3 to BHLF in Clone1pB

^5^ BART transcripts splice upstream from BWRF/BHRF in Clone1pB

^6^ BHLF transcripts splice from orilyt/LF3 to BHLF in CL1pB 424 (146303--143022 v 40093--37879)

The percentage of specific EBV reads indicates that both the AGS-EBV cell lines and tumors had expression of genes associated with viral replication ([Table 7](#ppat.1008071.t007){ref-type="table"}). One distinction is the greatly increased number of reads in the tumors representing BHRF1, the EBV bcl2 homologue \[[@ppat.1008071.ref017]\]. The other notable feature was the increase in reads from the BART region, which frequently represented 40--70% of transcription. In the C666 cell line, 90% of the reads were BART transcripts while in C17, only BART transcription was detected with 100% of the reads from the BART region. All of the AGS-EBV and Clone 1 tumors and cell lines had considerable expression of LMP2 ([Table 7](#ppat.1008071.t007){ref-type="table"}).

Quantitative expression of EBV transcription during tumor growth {#sec012}
----------------------------------------------------------------

A previous study had suggested that BART miRNA expression increased during tumor growth *in vivo* \[[@ppat.1008071.ref013]\]. To evaluate levels of expression, quantitative PCR was performed for several BART miRNAs, for two splices characteristic of the BART lnc RNAs between exons 4 and 5 and 6 and 7, and for LMP1 and LMP2 ([Fig 8](#ppat.1008071.g008){ref-type="fig"}). BART miRNAs increased approximately two fold to eight fold while the lnc splice junctions increased approximately 1.5 to 5 fold with significant p values. Expression of LMP1 and LMP2 remained low although they increased in clone 1 tumors which also had increased replicative expression.

![Quantitative PCR for representative BART miRs, splices for the BARTlnc transcripts, and EBV LMP1 and LMP2.\
Quantitative PCR comparing the fold change in expression in the AGS-EBV tumors in reference to the AGS-EBV cell line, and in the Clone 1 tumors in reference to the Clone 1 cell line, with the significant *p* values denoted.](ppat.1008071.g008){#ppat.1008071.g008}

Discussion {#sec013}
==========

In this study, AGS cells with or without EBV were inoculated into immunodeficient mice either subcutaneously or intraperitoneally. All inoculations formed tumors with slightly enhanced tumor growth in the cells containing EBV. Importantly, although the cells were not maintained under G418 selection, which is required to maintain the EBV genome *in vitro*, all EBV positive tumors contained and expressed viral genes without selection. This finding suggests that EBV is providing a survival advantage to the inoculated cells \[[@ppat.1008071.ref018]\]. This is perhaps related to the finding that NPC tumors usually lose the EBV genome when cultured *in vitro* \[[@ppat.1008071.ref006]\].

An intriguing difference in the EBV positive gastric tumors was the greatly increased amounts of blood and hemorrhage that was not greatly evidenced in the expression analyses. Identification of disease and function did identify increased hematologic system development and function ([Table 6](#ppat.1008071.t006){ref-type="table"}). A recent study identified vasculogenic mimicry in EBV-associated epithelial malignancies where the tumor cells develop vascular networks \[[@ppat.1008071.ref019]\]. The increased vascularization identified in our study substantiates this and that this difference was not due to infiltrating mouse cells ([Table 2](#ppat.1008071.t002){ref-type="table"}). However, the previous study linked this vascularization to activation of the Akt and HIF1-α pathways that were not identified in the analyses here where HIF1-α was predicted to be inhibited ([Table 5](#ppat.1008071.t005){ref-type="table"}). Activation of Akt was identified in Biojupes analyses that looked at the top 500 genes with increased expression. However, the previous study that identified vasculogenic mimicry primarily focused on NPC where LMP1 and LMP2 that are known to activate these pathways are expressed \[[@ppat.1008071.ref006], [@ppat.1008071.ref020]\]. In that study, the analyses of gastric tumors did identify activation of Akt and HIF1-α using immunohistochemistry on tumor samples. However, the expression of other viral genes was not assessed \[[@ppat.1008071.ref019]\]. It is possible that the same biologic effectors of Akt and HIF1-α are activated in the AGS-EBV gastric tumors through subtle effects of the noncoding RNAs.

Importantly, the data revealed major changes in cellular expression when grown as tumors in immunodeficient mice compared to cells cultured *in vitro*. Analysis of the global changes of expression greater than two fold revealed that many canonical pathways had significant numbers of genes with altered expression. Many of the genes might be expected as they would contribute to growth *in vitro*. In most of the identified pathways activation or inhibition was not apparent. Although the many pathways that are not predicted to be activated or repressed, the considerable number of genes within these pathways and the very significant p values suggest that they are altered during tumor growth. However, the majority of pathways that were significantly affected in both the EBV positive and negative AGS tumors were predicted to be repressed. The mice lack an immune system so that immune selection is unlikely, however, these findings suggest that there is an advantage to not have activation of the multiple pathways that are increased *in vitro*. Intriguingly, identification of the predicted upstream regulators within the tumors revealed induced expression of miRNAs. This suggests that noncoding RNAs are likely key regulators of the global changes in expression during tumor growth in the analysis of total transcriptional changes. It is possible that the noncoding RNAs may broadly affect cellular expression perhaps through epigenetic mechanisms \[[@ppat.1008071.ref012]\]. Additionally, HDAC1 is revealed to be an EBV unique upstream regulator in the AGS-EBV tumors also confirming the shift to epigenetic regulation during tumor formation ([Table 4](#ppat.1008071.t004){ref-type="table"}).

In contrast, hierarchical clustering revealed clear distinction that delineated the specific groups, NPC tumors, cell lines, and EBV positive and negative tumors ([Fig 4](#ppat.1008071.g004){ref-type="fig"}). The genes identified within the delineating regions identified activation of key biologic functions including differentiation, motility, metastasis, transformation. Importantly, most of the fold expression changes within the delineating regions were greater than 4 fold. In the gastric tumors, many of these genes are regulated by ETS2, BMP4, and TGFB1 and by the kinases MAPK1(ERK) and CCNK and the transcription regulators E2F, CBX5, and CCND1. The EBV negative tumors, the pathways were regulated by HNF1A, SIM1, IRF7, TCF7L2, and SMARCA4, as well as IFNG, CLDN7, and let-7.

The EBV positive samples also showed consistent up regulation or down regulation of certain genes, 240 in all, when compared to the EBV negative samples ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}). Many of the upregulated genes are involved in DNA replication and repair, RNA transactivation, and cell cycle progression, all programs that suggest a more proliferative state in the EBV infected tumors ([S3 Table](#ppat.1008071.s007){ref-type="supplementary-material"}). Interestingly, 2 proto-oncogenes, MYBL1 and RAF1 were consistently upregulated in the EBV positive tumors, and NACC1, which negatively regulates the tumor suppressor Gadd45/GIp1, was consistently upregulated ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}). Several of these upregulated genes are targets of miR-122 and let-7, both predicted to be uniquely activated in the EBV negative samples. Many of the genes down regulated in the EBV positive tumors are involved in immune response and movement. Interestingly, several of the genes such as TRIM24, EGLN3, FUT1, MUC20, GATA6, and S100P that were consistently down regulated in the EBV positive samples are also targets of the BART miRs ([S2 Table](#ppat.1008071.s006){ref-type="supplementary-material"}) \[[@ppat.1008071.ref021]\]. Also other predicted BART miR targets including DICER, CASP3, CDH1, TOMM22, and PAK2 were consistently down regulated (less than 2 fold) in the EBV positive gastric cell lines and tumors as compared to the EBV negative \[[@ppat.1008071.ref022]\]. This data suggests that the BART miRs may regulated gene expression not only at the translational level, but also at the transcriptional level. Another interesting comparison is identification of genes whose expression is changed in the same direction as within an EBV cell line expressing one form of the spliced BART lnc RNAs ([S6 Table](#ppat.1008071.s010){ref-type="supplementary-material"}) \[[@ppat.1008071.ref011]\]. Several of the downregulated genes, TFF1, SLPI, and MUC1 are found at the mucosal barrier; others are involved in cell adhesion, CEACAM5, MSLN, and PTPRH; and RNF144B is proapototic ([S6 Table](#ppat.1008071.s010){ref-type="supplementary-material"}). Of the possible BARTlnc targets that were upregulated, several, MPP2, S1PR2, and TSPAN9 are involved in proliferation, growth and motility ([S6 Table](#ppat.1008071.s010){ref-type="supplementary-material"}). In most cases, the genes affected in the lnc cell line were affected to a much greater level within the tumors. This suggests that within the tumors in the presence of all forms of the spliced BART RNAs and the BART miRNAs, the effects are considerably greater.

These data provide us new insight into EBV expression. The expression *in vivo* reveals how tightly latent the EBV NPC tumors are and that EBV leaky replicative expression remained detectable in the AGS-EBV tumors *in vivo*. The significance of the unusual splice linkages is unclear. They are not overwhelmingly abundant but may not be tabulated completely in this analysis. One intriguing fact is the more frequent linkage of orilyt/LF3 to BHLF1. An abundant circular RNA has been inferred from sequence analyses \[[@ppat.1008071.ref016]\]. The linkage between LF3 and BHLF1 may represent an unusual RNA, perhaps circular, that functions during replication. It is possible that this RNA may contribute in some replicative way to lytic origin function. However, overall these data affirm the importance of latent infection in tumorigenesis and strongly underscore the significance of the BART nc RNAs. It is possible that the tumor cells are epigenetically poised for further activation of expression due to the viral nc RNAs and that these global epigenetic effects on cellular expression are a major mechanism through which EBV contributes to tumorigenesis.

Materials and methods {#sec014}
=====================

Ethics statement {#sec015}
----------------

All animals at the University of North Carolina are maintained in compliance with the Animal Welfare Act and the Department of Health and Human Service "Guide for the Care and Use of Laboratory Animals." UNC's Animal Welfare Assurance Number is A3410-01. Animal experiments were performed in accordance with a protocol (\#17--031) approved by the Institutional Animal Care and Use Committee (IACUC) at the University of North Carolina. Mice were monitored daily following injection for signs of distress and tumor growth. At all monitoring intervals, post-injection general appearance and body weights were recorded. When the tumors reached approved endpoint growth or the animals were in distress the animals were euthanized by exposure to CO2 in a chamber, followed by injection of dormitory/ketaset (300mg/kg and 3mg/kg weight).

### Cell lines {#sec016}

AGS (EBV negative gastric carcinoma) cell line was grown in F-12 media (Life Technologies, Inc.) with 10% fetal bovine serum and antibiotic/antimycotic (Life technologies, Inc.), AGS-EBV (EBV+ gastric carcinoma (infected with EBV Akata BX1) and Clone 1 (EBV^+^ clone from AGS-EBV cell line have been previously described \[[@ppat.1008071.ref023]\] and were maintained with 500ug/ml G418 (Life Technologies, Inc.). Stable AGS-EBV and Clone 1 cell lines containing EBV LMP1 were generated by transduction of the pBabe control or HA tagged pBabe-LMP1(B95 strain) constructs and selected with 1ug/ml puromycin; and the C666.1 (EBV^+^ NPC) cell line was maintained in RPMI 1640 (Life Technologies, Inc.) with 10% fetal bovine serum and antibiotic/antimycotic (Life Technologies, Inc.) \[[@ppat.1008071.ref024]\].

### Injections {#sec017}

1 x 10^7^ cells were injected either intraperitoneal (ip) or subcutaneous (sc) into NOD scid gamma (NSG) mice. Mice were monitored for tumor growth and illness, and tumor and spleen tissues were harvested at the end point. Splenocytes from a primary tumor that developed from the injection of the C666.1 cell line were purified and reinjected into 2 NSG mice.

### RNA sequencing {#sec018}

RNA was prepared from tumors that developed in the mice using Trizol reagent (Life Technologies, Inc). Poly(A)-selected, bar-coded, cDNA libraries were prepared using a TruSeq Stranded mRNA kit (Illumina) and the libraries were sequenced using a HiSeq4000 instrument (Illumina) using paired-end 75-bp sequencing by the UNC High-Throughput Sequencing facility. RNA was also prepared and analyzed as above from tumors from the NPC xenografts C15 and C17.

### Bioinformatics {#sec019}

RNA sequencing reads were aligned to the human genome (hg19) and the mouse genome (mm9) using the splicing aware read aligner TopHat on the Galaxy suite at [https://usegalaxy.org](https://usegalaxy.org/) \[[@ppat.1008071.ref025]\]. Aligned reads were mapped to specific human or mouse Refseq genes using the Partek Genomics Suite, which was also used to calculate differentially expressed genes and to perform principal component analysis. In order to quantify and visualize reads from the EBV Akata genome, RNA sequencing reads that did not map to the human genome were aligned to the Akata genome (Genbank accession number KC207813.1) using TopHat, and transcripts assembled using Cufflinks, and further assembled and quantified using Stringtie on the Galaxy suite. EBV aligned transcripts were visualized from the TopHat assemblies using the Integrative Genomics Viewer. Enriched molecular functions and pathways for the human and mouse data were obtained by running a core analysis on the differentially expressed genes using Ingenuity Pathway Analysis (IPA) software (Qiagen).

The gene rpkms against the human and mouse genomes were also analyzed in Biojupies, a web based program available at <https://amp.pharm.mssm.edu/biojupies/> \[[@ppat.1008071.ref026]\].

Hierarchical clustering maps and volcano plots were generated. Upstream regulators (transcription factors and kinases) as well as cellular pathways were determined and used to strengthen the data from the Partek and IPA analysis.

The RNA sequencing files for the transcriptome analysis of the gastric samples are available at SRA accession PRJNA503182. The RNA sequencing files for the transcriptome analysis of the NPC samples are available at SRA accession PRJNA501807.

### Western blotting {#sec020}

Protein lysates were prepared from the tumor tissue, by re-suspending pulverized tissue in RIPA buffer. Western blotting was performed as previously described \[[@ppat.1008071.ref027]\]. Primary antibodies used were mouse α-PCNA (Santa Cruz, sc-56) and mouse α-HSC70 (Santa Cruz, sc-7298).

### Quantitative RT-PCR {#sec021}

Total RNA was prepared from the tumors and cell lines using Trizol reagent (Invitrogen). Quantitative RT-PCR was performed for the BART miRNAs and the BART lncRNA using the miScript system (Qiagen) and Quantifast SYBR green RT-PCR kit (Qiagen) on a QuantStudio 6 Flex real-time PCR system (Applied Biosystems) as described previously \[[@ppat.1008071.ref028]\].

### 2-D Difference gel electrophoresis {#sec022}

Proteins isolated from cell or tumor samples were cleaned by methanol/chloroform precipitation and dissolved in lysis buffer (9M urea, 2M Thiourea, 20 mM tris-HCl, pH 8.5, 2% CHAPS, and 60 mM n-Octyl-β-D-glucopyranoside). Aliquots (35 μg) of replicates from each tumor or cell line group were labeled with 200 pmol either Cy3 or Cy5 fluorescent dyes, alternating Cy3 and Cy5 between replicates. An internal control (IC) was prepared by pooling equal amounts of protein (18.5 μg) from all samples, and then labeled with 200 pmol of Cy2 for every 15 μg of protein. The labeling reaction was carried out on ice for 30 min, protected from light, and quenched by the addition of 1 μL of 10mM followed by 10 min on ice. After labeling, corresponding samples were combined so that each gel contained an IC (Cy2) and two samples from different groups (Cy3 and Cy5). An equal volume of 2X sample buffer (9M urea, 2M Thiourea, 2% CHAPS, and 60 mM n-Octyl-β-D-glucopyranoside, 30 mg/mL DTT, 2% (v/v) IPG buffer 3--10) was added and the mixture was placed on ice for 15 min. Rehydration buffer (9M urea, 2M Thiourea, 2% CHAPS, and 60 mM n-Octyl-β-D-glucopyranoside, 15 mg/mL DTT, 2% (v/v) IPG buffer 3--10) was then added to a final volume of 450 μL.

The resulting mix was loaded onto an immobilized pH gradient (IPG) strip (24 cm, pI range 3--10) and the strip allowed to re-hydrate overnight at room temperature. Isoelectric focusing and the subsequent SDS-PAGE, using precast 12.5% gels (Jule Biotechnologies Inc.), were performed as originally described \[[@ppat.1008071.ref029]\]. Following SDS-PAGE gels were scanned using a Typhoon Trio Plus scanner (GE Healthcare) and analyzed using DeCyder 7.0 software (GE Healthcare).

Supporting information {#sec023}
======================

###### Canonical pathways predicted for the AGS-EBV tumors vs AGS tumors.

Canonical pathways associated with human genes with 2-fold expression change by RNA-seq in the AGS-EBV and Clone 1 and pB derivative tumors when compared to the AGS tumors. (A) Top canonical pathways associated with AGS-EBV tumors compared to AGS tumors. (B) Significant canonical pathways (absolute z-score ≥2) associated with AGS-EBV tumors compared to AGS tumors. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set represented in the pathway.

(TIF)

###### 

Click here for additional data file.

###### Canonical pathways predicted for C666.1 tumors vs C666.1 cell line.

Top canonical pathways associated with human genes with 2-fold expression change by RNA-seq in the C666.1 tumors when compared to the C666.1 cell line. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set that are represented in the pathway.

(TIF)

###### 

Click here for additional data file.

###### Significant canonical pathways predicted for the NPC tumors vs gastric tumors.

A. Significant canonical pathways predicted for the NPC tumors vs the AGS tumors. Significant canonical pathways (absolute z-score ≥2) associated with the human genes with 2-fold expression change by RNA-seq in the NPC tumors when compared to the AGS tumors. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set that are represented in the pathway. Astericks (\*) denote pathways unique to the comparison of NPC tumors to AGS tumors. B. Significant canonical pathways predicted for the NPC tumors vs the AGS-EBV tumors. Significant canonical pathways (absolute z-score ≥2) associated with the human genes with 2-fold expression change by RNA-seq in the NPC tumors when compared to the AGS-EBV tumors. The height of the bars reflects the p value, and the orange boxes reflect the ratio of the number of genes in the data set that are represented in the pathway. Astericks (\*) denote pathways unique to the comparison of NPC tumors to AGS-EBV tumors.

(TIF)

###### 

Click here for additional data file.

###### Visualization of the EBV reads from the EBV^+^ gastric tumors.

Mapped reads of AGS-EBV cell lines and tumors mapped to the Akata genome. The number of reads correlate with the height of the blue peaks.

(TIF)

###### 

Click here for additional data file.

###### Predicted common and unique upstream regulators in gastric tumors vs cell lines.

(DOCX)

###### 

Click here for additional data file.

###### Genes changed in the same direction in all EBV^+^ samples as compared to EBV^-^ samples.

Shown are the genes consistently upregulated or down regulated in all the EBV^+^ samples with the fold expression change.

(DOCX)

###### 

Click here for additional data file.

###### Disease and functions predicted for the 240 genes consistently changed in EBV^+^ samples.

A. Disease and functions predicted by IPA for the 166 genes upregulated in all EBV^+^ samples. B. Disease and functions predicted by IP for the 74 genes down regulated in all EBV^+.^

(DOCX)

###### 

Click here for additional data file.

###### Top 200 changed genes in each data set.

A. List of top 100 down regulated genes in each data set and the fold change range. B. List of the top 100 upregulated genes in each data set and the fold change range.

(DOCX)

###### 

Click here for additional data file.

###### Disease and functions of the top 100 upregulated genes in the AGS-EBV cell lines and tumors.

A. Disease and functions of the top 100 upregulated genes in the AGS-EBV cell lines compared the AGS cell line. B. Disease and functions of the top 100 upregulated genes in the AGS-EBV tumors compared to the AGS tumors.

(DOCX)

###### 

Click here for additional data file.

###### Correlation with potential BARTlnc targets.

List of genes changed at least 1.5 fold in the EBV^+^ cell lines, EBV^+^ tumors and the BART cell line \[[@ppat.1008071.ref011]\] when compared to the EBV^-^ control. P values and fold changes are denoted.

(DOCX)

###### 

Click here for additional data file.

Dr. Judith Nielson for identification of mitotic figures and pathology, and the UNC Animal Core Facility

[^1]: The authors have declared that no competing interests exist.
